CHARACTERISTICS OF WOMEN WITH A FAMILY HISTORY OF OVARIAN-CANCER .2. FOLLICULAR PHASE HORMONE LEVELS

被引:0
|
作者
CRAMER, DW [1 ]
BARBIERI, RL [1 ]
MUTO, MG [1 ]
KELLY, A [1 ]
BRUCKS, JP [1 ]
HARLOW, BL [1 ]
机构
[1] BRIGHAM & WOMENS HOSP, DEPT OBSTET & GYNECOL, BOSTON, MA 02115 USA
关键词
OVARIAN CANCER; GONADOTROPINS; CA; 125; FAMILIAL; ESTRADIOL; GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE;
D O I
10.1002/1097-0142(19940815)74:4<1318::AID-CNCR2820740422>3.0.CO;2-V
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Although there is a basis for linking pituitary or ovarian hormones with experimentally induced ovarian cancer, establishing their role in women is complicated because the usual case-control methods cannot be applied. In this study, hormonal levels in women with a family history of ovarian cancer (FOC) and who are at higher risk for the disease are compared with women without such a history. Methods. The authors studied 106 unrelated women (FOC patients) with at least one primary or two second-degree relatives with ovarian cancer compared with 116 age- and residence-matched controls without a family history of ovarian cancer (FOC control subjects). All women were premenopausal, between the ages of 25 and 49 years, not currently using oral contraceptives, and had blood drawn during the early follicular phase for gonadotropins, estradiol (E(2)), and CA-125. Results. Women with a family history of ovarian cancer and control subjects did not differ significantly in follicle stimulating hormone (FSH) levels, E(2), or CA-125. Patients with a family history of ovarian cancer had significantly lower luteinizing hormone (LH) levels compared with control subjects and produced more E(2) and FSH relative to their level of LH. The ratios of LH to E(2) and LH to FSH were correlated with the enzymatic activity of galactose-1-phosphate uridyl transferase, which was shown previously to differ between FOC patients and control subjects. Conclusion. Lower LH and higher E(2) are reported in women with breast, endometrial, and ovarian cancer (before surgery). The authors speculate that these observations reflect greater LH binding and estradiol production in ovaries at risk for these cancers-the ovarian cortical hyperplasia postulated in older gynecologic literature as the precursor to estrogen dependent neoplasia.
引用
收藏
页码:1318 / 1322
页数:5
相关论文
共 46 条
  • [41] Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer
    Noonan, Anne M.
    Bunch, Kristen P.
    Chen, Jin-Qiu
    Herrmann, Michelle A.
    Lee, Jung-Min
    Kohn, Elise C.
    O'Sullivan, Ciara C.
    Jordan, Elizabeth
    Houston, Nicole
    Takebe, Naoko
    Kinders, Robert J.
    Cao, Liang
    Peer, Cody J.
    Figg, W. Douglas
    Annunziata, Christina M.
    CANCER, 2016, 122 (04) : 588 - 597
  • [42] Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
    Bellet, Meritxell
    Gray, Kathryn P.
    Francis, Prudence A.
    Lang, Istvan
    Ciruelos, Eva
    Lluch, Ana
    Angel Climent, Miguel
    Catalan, Gustavo
    Avella, Antoni
    Bohn, Uriel
    Gonzalez-Martin, Antonio
    Ferrer, Roser
    Catalan, Roberto
    Azaro, Analia
    Rajasekaran, Agnita
    Morales, Josefa
    Vazquez, Josep
    Fleming, Gini F.
    Price, Karen N.
    Regan, Meredith M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : 1584 - U89
  • [43] BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin
    Rosaria Solano, Angela
    Maria Aceto, Gitana
    Delettieres, Dreanina
    Veschi, Serena
    Isabel Neuman, Maria
    Alonso, Eduardo
    Chialina, Sergio
    Daniel Chacon, Reinaldo
    Renato, Mariani-Costantini
    Jorge Podesta, Ernesto
    SPRINGERPLUS, 2012, 1
  • [44] A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer
    Rustin, G.
    Vergote, I.
    Micha, J. P.
    Duska, L. R.
    Reed, N.
    Bendell, J.
    Spitz, D.
    Dark, G.
    Hoch, U.
    Tagliaferri, M.
    Hannah, A. L.
    Garcia, A. A.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (02) : 276 - 282
  • [45] Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
    Evans, D. G. R.
    Moran, A.
    Hartley, R.
    Dawson, J.
    Bulman, B.
    Knox, F.
    Howell, A.
    Lalloo, F.
    BRITISH JOURNAL OF CANCER, 2010, 102 (07) : 1091 - 1098
  • [46] A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer
    Vergote, Ignace
    Heitz, Florian
    Buderath, Paul
    Powell, Matthew
    Sehouli, Jalid
    Lee, Christine M.
    Hamilton, Anne
    Fiorica, James
    Moore, Kathleen N.
    Teneriello, Michael
    Golden, Lisa
    Zhang, Wei
    Pitou, Celine
    Bell, Robert
    Campbell, Robert
    Farrington, Daphne L.
    Bell-McGuinn, Katherine
    Wenham, Robert M.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 23 - 31